President and Chief Operating Officer Jere Goyan, PhD, assumes additional post of acting CEO. Goyan is a former FDA commissioner. The action follows the announcement that Chairman and CEO Carl Faden, a company founder, will retire at the end of 1994. Upon his retirement, Faden will become chairman emeritus and a consultant to the Northvale, N.J.-based development stage company that focuses on products for diabetes and aging complications.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth